B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
T Shaw, J Quan, MC Totoritis - Annals of the rheumatic diseases, 2003 - ard.bmj.com
Rheumatoid arthritis (RA) is a complex condition that is well characterised by chronic
inflammation in the synovial membrane of affected joints, often with systemic manifestations. Yet …
inflammation in the synovial membrane of affected joints, often with systemic manifestations. Yet …
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial …
…, EW Hessey, T Shaw, MC Totoritis - Arthritis & …, 2006 - Wiley Online Library
… Totoritis own stock in Biogen Idec. Mr. Shaw owns stock in … Totoritis own stock in Biogen
Idec. Mr. Shaw owns stock in … Totoritis own stock in Biogen Idec. Mr. Shaw owns stock in Roche. …
Idec. Mr. Shaw owns stock in … Totoritis own stock in Biogen Idec. Mr. Shaw owns stock in Roche. …
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: a randomized, double‐blind, placebo‐controlled trial
…, JC Davis Jr, JT Merrill, MC Totoritis… - Arthritis & …, 2002 - Wiley Online Library
Objective To evaluate the safety and efficacy of a humanized monoclonal antibody against
CD154 (IDEC‐131) in patients with active systemic lupus erythematosus (SLE). Methods In …
CD154 (IDEC‐131) in patients with active systemic lupus erythematosus (SLE). Methods In …
Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
JC Davis, MC Totoritis, J Rosenberg… - The Journal of …, 2001 - jrheum.org
OBJECTIVE: To investigate the safety and pharmacology of a humanized monoclonal
antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus (SLE). …
antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus (SLE). …
Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial
…, RG Lizambri, TA Olejnik, MC Totoritis - Journal of Allergy and …, 2003 - Elsevier
BACKGROUND: CD23, a cell-surface molecule, is involved in a variety of pathways likely to
influence IgE production and inflammation in allergic disorders, such as allergic rhinitis and …
influence IgE production and inflammation in allergic disorders, such as allergic rhinitis and …
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial
…, R Levy, J Baker, Y Hardiman, MC Totoritis… - Annals of Allergy …, 2014 - Elsevier
Background Hereditary angioedema (HAE), caused by C1 inhibitor (C1INH) deficiency or
dysfunction, is characterized by recurrent attacks of tissue swelling affecting multiple anatomic …
dysfunction, is characterized by recurrent attacks of tissue swelling affecting multiple anatomic …
A population pharmacokinetic‐pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis
…, MJ Elliott, ME Luggen, MC Totoritis - Clinical …, 1999 - Wiley Online Library
Clenoliximab (IDEC‐151) is a macaque‐human chimeric monoclonal antibody (immunoglobulin
G4) specific for the CD4 molecule on the surface of T lymphocytes. It is being studied in …
G4) specific for the CD4 molecule on the surface of T lymphocytes. It is being studied in …
Association of antibody to histone complex H2A–H2B with symptomatic procainamide-induced lupus
MC Totoritis, EM Tan, EM McNally… - New England Journal of …, 1988 - Mass Medical Soc
Antinuclear antibodies develop in most patients who are given prolonged procainamide
therapy, but clinical symptoms resembling those of lupus appear in only 15 to 20 percent of such …
therapy, but clinical symptoms resembling those of lupus appear in only 15 to 20 percent of such …
Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double‐blind, placebo‐controlled phase 3 study
…, RG Bagin, ED Ballard, MC Totoritis - Journal of travel …, 2014 - academic.oup.com
Background Rifamycin SV is under development for treatment of travelers' diarrhea (TD) in
a new oral formulation, Rifamycin SV MMX ® (RIF‐MMX; Santarus Inc., San Diego, CA, USA), …
a new oral formulation, Rifamycin SV MMX ® (RIF‐MMX; Santarus Inc., San Diego, CA, USA), …
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
…, AA Abdulghani, M Goldfarb, N Chieffo, MC Totoritis - Clinical …, 2004 - Elsevier
Background: Reduction in lesional, activated T cells induces improvement in psoriatic
plaques. Galiximab (IDEC-114), an IgG 1 anti-CD80 antibody, binds to CD80, a costimulatory …
plaques. Galiximab (IDEC-114), an IgG 1 anti-CD80 antibody, binds to CD80, a costimulatory …